

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ARGENTUM PHARMACEUTICALS LLC,
Petitioner

v.

COSMO TECHNOLOGIES LIMITED,
Patent Owner.

U.S. Patent No. 9,320,716 to Villa *et al.*

Issue Date: April 26, 2016

Title: Controlled Release and Taste Masking Oral Pharmaceutical Compositions

Inter Partes Review No.: IPR2018-00080

DECLARATION OF HARTMUT DERENDORF, PH.D

Exhibit 1006
ARGENTUM

Table of Contents

I.	INTRODUCTION	1
II.	MY EXPERIENCE AND QUALIFICATIONS	2
III.	LIST OF MATERIALS CONSIDERED	6
IV.	LEGAL STANDARD	10
	A. Anticipation	10
	B. Obviousness	11
V.	PERSON OF ORDINARY SKILL IN THE ART (“POSA”).....	13
VI.	THE VILLA PATENTS	14
VII.	CLAIM CONSTRUCTION	18
VIII.	SCOPE AND CONTENT OF THE PRIOR ART	20
	A. Controlled Release Oral Compositions	20
	B. Budesonide	24
IX.	INVALIDITY OF THE ’716 PATENT	24
	A. The ’584 Patent Anticipates Claims 1-29 of the ’716 Patent ...	24
	1. Independent Claims.....	24
	2. Dependent Claims	34
	B. The ’584 Patent Renders Obvious Claims 1-29 of the ’716 Patent	
	38
	1. Claim 1	39
	2. Claims 6, 12, and 22: “at least one amphiphilic	
	compound”	46
	3. Claims 2 and 13: “wherein the gastro-resistant coating is	
	. . . methacrylic acid polymers and cellulose	
	derivatives”	48
	4. Claims 3-5 and 14-16: “wherein the at least one	
	hydrophilic compound is . . . a hydroxyalkyl cellulose”	49
	5. Claims 7, 8, 17 and 18: “wherein the at least one	
	amphiphilic compound . . . lecithin”	50

Declaration of Hartmut Derendorf, Ph.D.

6.	Claims 9, 10, 19 and 20: “wherein the at least one lipophilic compound is selected from the group consisting of an unsaturated or hydrogenated alcohol or fatty acid, salt, ester, or amide thereof . . .”/”lipophilic compound is stearic acid”	51
7.	Claims 11, 21 and 23: “The controlled release oral pharmaceutical composition . . . further comprising . . . an acrylic acid polymer”	52
8.	Claims 24, 25 and 26: “wherein the macroscopically homogenous structure comprises microcrystalline cellulose”	53
9.	Claims 27, 28 and 29: “A method for treating intestinal inflammatory disease comprising administering to a patient the controlled release oral pharmaceutical composition according to claim [1/12/22]”	53
10.	Reasonable Expectation of Success	54
C.	The ’388 Patent Anticipates Claims 1-7, 9, 11-17, 19, and 21-29 of the ’716 Patent	54
1.	Independent Claims	54
2.	Dependent Claims	64
D.	The ’388 Patent Renders Obvious Claims 1-29 of the ’716 Patent	67
1.	Claim 1	68
2.	Claims 6, 12, and 22: “at least one amphiphilic compound”	72
3.	Claims 2 and 13: “wherein the gastro-resistant coating is . . . methacrylic acid polymers and cellulose derivatives”	73
4.	Claims 3-5 and 14-16: “wherein the at least one hydrophilic compound is . . . a hydroxyalkyl cellulose”	73
5.	Claims 7, 8, 17 and 18: “wherein the at least one amphiphilic compound is . . . [phosphatidylcholines/lecithin]”	74
6.	Claims 9, 10, 19 and 20: “wherein the at least one lipophilic compound is selected from the group consisting of an unsaturated or hydrogenated alcohol or fatty acid, salt, ester, or amide thereof . . . “/”lipophilic compound is stearic acid”	75

Declaration of Hartmut Derendorf, Ph.D.

7.	Claims 11, 21 and 23: “The controlled release oral pharmaceutical composition . . . further comprising . . . an acrylic acid polymer”	76
8.	Claims 24, 25 and 26: “wherein the macroscopically homogenous structure comprises microcrystalline cellulose”	77
9.	Claims 27, 28 and 29: “A method for treating intestinal inflammatory disease comprising administering to a patient the controlled release oral pharmaceutical composition according to claim [1/12/22]”	78
10.	Reasonable Expectation of Success	78
E.	The ‘388 Patent in View of the ’584 Patent Renders Obvious Claims 8, 10, 18, and 20 of the ’716 Patent	79
1.	Claims 8 and 18: wherein the at least one amphiphilic compound is lecithin”	79
2.	Claims 10 and 20: “wherein the at least one lipophilic compound is stearic acid”	80
X.	[Intentionally blank]	81
	[Paragraphs 129-195 intentionally omitted]	81
XI.	SECONDARY CONSIDERATIONS	81

I, Hartmut Derendorf, Ph.D., do hereby declare and state as follows:

1. I understand that Petitioner Argentum is seeking to join IPR2017-01035, in which the petitioner, Mylan, relies on the expert testimony of Dr. Palmieri. For that reason, my testimony below repeats verbatim Dr. Palmieri's declaration testimony from IPR2017-01035, with the exception of omitting testimony related to a second patent not the subject of this IPR petition, and reciting my own background and qualifications instead of those of Dr. Palmieri. I provide this testimony below:

I. INTRODUCTION

2. I am over the age of eighteen (18) and otherwise competent to make this Declaration.

3. My services have been retained on behalf of Petitioner for the above-captioned *inter partes* reviews ("IPRs"). Our consulting company is being compensated for my time in connection with this IPR at my standard consulting rate, which is \$600 per hour for all work conducted in this matter and \$6000 per day for deposition. This compensation does not depend in any way on the outcome of any of the IPRs.

4. It is my understanding that the Petition for *Inter Partes* Review in this matter involves U.S. Patent No. 9,320,716 ("the '716 patent") (EX1001).

5. The '716 Patent names Roberto Villa, Massimo Pedrani, Mauro Ajani, and Lorenzo Fossati as the purported inventors. I understand that the '716 patent is

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.